Biotech entity

mifepristone

Product

pharma is the sole category represented across all 5 tracked stories. Sentiment skews more negative than the wider beat, at 60% negative against 18% across all 178 Biotech stories in the same window. Across a 12-day span, the pace is roughly 2.9 stories per week. The busiest single day carried 2.

Last mentioned: Mar 24, 2026

Entity pulse

Recent coverage · mifepristone

5 stories
7 avg impact
0% positive
60% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 60 percentage points.

  • 40% neutral
  • 60% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about mifepristone

pharma is the sole category represented across all 5 tracked stories. Sentiment skews more negative than the wider beat, at 60% negative against 18% across all 178 Biotech stories in the same window. Across a 12-day span, the pace is roughly 2.9 stories per week. The busiest single day carried 2. mifepristone is most often covered alongside FDA, which appears in 2 of these 5 stories. Each story carries 3.2 original sources on average, compared with 3.4 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6.1 for that window. This profile follows 5 Biotech stories mentioning mifepristone across the period from March 13, 2026 to March 24, 2026.

Stories tracked
5
Per week
2.9
Negative
60%
Sources per story
3.2

Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 178 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering mifepristone. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Media Backlash

    Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.

  2. Bill Introduction

    Rep. Mary Miller introduces the Clean Water For All Life Act in the House.

  3. Press Conference

    Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.

  4. Law Signed

    Governor signs the law, enabling the Department of Corrections to begin distribution to providers.

  5. Legislation Passed

    Washington legislature passes bill to clarify state distribution authority.

  6. Missouri Pause Request

    DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.

  7. Hawley Federal Bill

    Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.

  8. Louisiana Pause Request

    DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.

  9. Missouri Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.

  10. SCOTUS Ruling

    Supreme Court preserves access to mifepristone on standing grounds, but litigation continues.

  11. SCOTUS Ruling

    Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.

  12. Initial Stockpile Purchase

    Governor Inslee orders 30,000 doses of mifepristone following a Texas court ruling.

  13. Dobbs Decision

    SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.

  14. Telehealth Shift

    FDA permanently removes the requirement that mifepristone be dispensed in person.

  15. Label Update

    FDA expands usage to 70 days gestation and reduces required office visits.

  16. FDA Approval

    FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.

Stories mentioning mifepristone 5

Pharma Neutral

Medication Abortion Dominates US Market Amid Escalating Regulatory Warfare

Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.

2 sources
Pharma Strongly negative

Georgia Murder Charge Over Abortion Pills Signals New Pharma Legal Risks

A Georgia woman has been charged with murder after allegedly using medication to induce an abortion, marking a significant escalation in the criminalization of self-managed reproductive care. This case highlights the growing legal and regulatory volatility surrounding the distribution and use of FDA-approved abortion pills in restrictive jurisdictions.

7 sources

Source: abc15.com · citizensvoice.com

Pharma Negative

GOP Bill Targets Abortion Pill Access via Environmental Water Safety Regulations

House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.

3 sources
Pharma Neutral

Washington State Law Streamlines Abortion Pill Stockpile Distribution

Washington Governor has signed legislation authorizing the state to distribute its 30,000-dose stockpile of mifepristone to private and non-profit healthcare providers. The law resolves previous licensing hurdles that prevented the state's Department of Corrections from acting as a wholesale distributor for reproductive health medications.

2 sources
Pharma Negative

DOJ Seeks Pause in Missouri Mifepristone Suit Amid FDA Review Strategy

The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.

2 sources

mifepristone is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.